CytoAgents Revenue and Competitors
Estimated Revenue & Valuation
- CytoAgents's estimated annual revenue is currently $1M per year.
- CytoAgents's estimated revenue per employee is $111,944
- CytoAgents's total funding is $10.2M.
Employee Data
- CytoAgents has 9 Employees.
- CytoAgents grew their employee count by -18% last year.
CytoAgents's People
| Name | Title | Email/Phone |
|---|
CytoAgents Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.6M | 7 | -12% | N/A | N/A |
#2 | $4M | 38 | 81% | N/A | N/A |
#3 | N/A | 76 | 27% | N/A | N/A |
#4 | $0.9M | 5 | 0% | N/A | N/A |
#5 | $1.1M | 8 | 33% | N/A | N/A |
#6 | $10.9M | 61 | 7% | N/A | N/A |
#7 | $0.7M | 9 | 29% | N/A | N/A |
#8 | $4M | 20 | -5% | N/A | N/A |
#9 | $1.7M | 11 | 22% | N/A | N/A |
#10 | $7.6M | 49 | 2% | N/A | N/A |
What Is CytoAgents?
CytoAgents is a clinical stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of life-threatening symptoms associated with Cytokine Release Syndrome (CRS), an overreaction of the immune system causing systemic inflammation. There are many causes of CRS and our mission is to develop a broadly accessible treatment for multiple indications of high unmet need. Using a novel approach by calming the natural immune response to a multi organ disease, CytoAgemts' lead drug candidate, GP1681, is positioned to become a new best practice in medicine.
keywords:N/A
$10.2M
Total Funding
9
Number of Employees
$1M
Revenue (est)
-18%
Employee Growth %
N/A
Valuation
N/A
Accelerator
CytoAgents News
cytoagents.com, $100,000, 5, $100,000, Clinical stage biotechnology company focused on the development of innovative pharmaceutical products...
Other Companies in Pittsburgh
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.7M | 9 | 0% | N/A |
#2 | $0.4M | 9 | -10% | $10.3M |
#3 | $0.7M | 9 | 0% | N/A |
#4 | $0.9M | 9 | -10% | N/A |
#5 | $0.4M | 9 | 50% | N/A |